Sex: F
Vaccine: COVID19
Symptoms: Mydriasis, Skin wrinkling, Swelling, Swelling face
Clinical narrative: muscle weakness; muscle pain; severe weakness; I had a little bit of swelling in my face/swelling in her face; my pupils got really dilated/her pupils were dilated; My nose was swollen; my wrinkles were not there, from the swelling they were opened up; This is a spontaneous report from a contactable nurse (patient). A 68-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on 23Jan2021 as single dose for COVID-19 immunisation. The patient's medical history included chemotherapy, history of allergic reactions to CT dye, history of cancer. She has never had a reaction to a vaccine in the past and she has been able to receive PEG in the past. The patient's concomitant medications were not reported. Upon follow up on 22Feb2021, it was reported that, she took the first Pfizer COVID vaccine and she had some effects from it. Not anaphylaxis, on 23Jan2021, she had a little bit of swelling in face and this was not immediately, this happened a couple of hours afterwards and pupils got really dilated and then that went away in a couple of hours. And then three days later on 26Jan2021, she came down with muscle weakness and muscle pain and all of that lasted three weeks but she had not concerned about that. She has concerned about is that like the people said that and the face swelling, if you would have looked at me, you would not have known that face was swollen but it was. Her nose was swollen, wrinkles were not there, from the swelling they were opened up." She went back to get second vaccine and they were hesitant about giving it to because the doctor there said that there was a good possibility that the second dose could give a full blown anaphylaxis reaction. So, they were kind of hesitant about it. So, they made another appointment for 3 weeks later because they said as long as she gets it in 6 weeks, she is still good. But they also told to take a series of blood tests that would tell what level is, the number level and they said as long as it is not falling after 6 weeks then that means she have enough immunity. The way he explained it to was that if you have to put a 100 people in a room and give them the vaccine, considerably they already have 95 percent and the other have lost so that's why she has to get the shot to everybody. So, she had the first test done and result was 108 which was high because 'anything that has 0.79 is positive' (not confirmed appropriately) and she have to get another blood test tomorrow. But she thinks need a little bit direction and also read that the blood test doesn't really tell you how much immunity you have towards the shot. Upon follow up on 25Feb2021, it was reported that getting first Pfizer Covid vaccine dose on 23Jan2021. 1.5 hours after her dose she had swelling in her face and pupils were dilated. 3 days later she developed severe weakness and muscle pain which lasted for 3 weeks. The patient underwent lab tests and procedures which included antibody test: 108; blood test: 108. The reporter considered events as non-serious. The outcome of I had a little bit of swelling in my face/swelling in her face, my nose was swollen, my wrinkles were not there, from the swelling they were opened up was unknown, while with other events was recovered on an in specified date in 2021.  Follow-up (18Feb2021): Follow-up attempts completed. No further information is expected.  Follow up (22Feb2021): The initial case was missing the following minimum criteria: Adverse effect. Upon receipt of follow-up information on 22Feb2021, this case now contains all required information to be considered valid.New information received from a contactable nurse (patient) included: Added new events (I had a little bit of swelling in my face/swelling in her face, my pupils got really dilated/her pupils were dilated, muscle weakness, muscle pain, my nose was swollen, my wrinkles were not there, from the swelling they were opened, severe weakness), lab data and clinical information.  Follow-up (25Feb2021): New information received from a contactable Nurse (patient) included: Updated patient age, added dosage regimen details of first dose of BNT162B2 (start/stop date), medical history and clinical information.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.